Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE versus NARCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE versus NARCAN.
NALOXONE HYDROCHLORIDE vs NARCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Opioid receptor antagonist; binds competitively to mu, kappa, and delta opioid receptors, reversing opioid effects.
0.4 mg to 2 mg intravenous, intramuscular, or subcutaneous every 2 to 3 minutes as needed for opioid reversal; may repeat until response achieved. For continuous infusion, 0.25-6.25 mg/hour IV.
Initial dose: 0.4 mg to 2 mg IV, IM, or SC, repeated every 2 to 3 minutes as needed. For opioid-induced respiratory depression, may use 0.1 to 0.2 mg IV increments in patients with opioid dependence to avoid withdrawal.
None Documented
None Documented
Terminal elimination half-life is 1–1.5 hours in adults; shorter in neonates (approx. 3 hours due to immature clearance). Clinically, rapid decline limits duration of antagonism.
Approximately 1 hour in adults; context: shorter than most opioids (e.g., morphine 2-4 h), necessitating repeated doses for prolonged opioid effects.
Primarily hepatic metabolism (glucuronidation) with renal excretion of metabolites. ~70% as naloxone-3-glucuronide in urine, <5% unchanged. Minor fecal elimination (<10%).
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites; <5% excreted unchanged in urine.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist